Table 1 Clinical characteristics and preoperative treatments^a

Age^b (year)

56.0 (27.0–78.0)

56.0 (26.0–76.0)

58.5 (41.0–75.0)

56.0 (26.0–78.0)

0.467

Gender

0.452

     Male

36 (59.0)

31 (70.5)

7 (70.0)

74 (64.3)

     Female

25 (41.0)

13 (29.5)

3 (30.0)

41 (35.7)

BMI before surgery^b (kg/m²)

21.9 (17.3–30.7)

23.1 (17.1–32.4)

21.1 (16.9–29.0)

22.3 (16.9–32.4)

0.272

Tumor location

0.109

     Proximal one-third

12 (19.7)

21 (47.7)

2 (20.0)

35 (30.4)

     Middle one-third

18 (29.5)

8 (18.2)

3 (30.0)

29 (25.2)

     Distal one-third

23 (37.7)

12 (27.3)

4 (40.0)

39 (33.9)

     Whole

8 (13.1)

3 (6.8)

1 (10.0)

12 (10.4)

Preoperative treatment

0.881

     PCT

50 (82.0)

34 (77.3)

8 (80.0)

92 (80.0)

     PCRT

11 (18.0)

10 (22.7)

2 (20.0)

23 (20.0)

     Cycles^b

5.0 (2.0–20.0)

7.0 (2.0–19.0)

7.5 (2.0–21.0)

5.0 (2.0–21.0)

0.082

     Duration^b (month)

3.1 (1.2–15.6)

4.5 (1.2–18.0)

5.4 (1.2–15.2)

3.6 (1.2–18.0)

0.061

     Interval time^b (month)

1.1 (0.4–5.7)

1.0 (0.4–4.5)

1.2 (0.5–2.4)

1.1 (0.4–5.7)

0.167

Chemotherapy regimen

0.922

     Platinum-containing

38 (62.3)

25 (56.8)

8 (80.0)

71 (61.7)

     Taxane-containing

7 (11.5)

6 (13.6)

1 (10.0)

14 (12.2)

     Containing both platinum and taxane

14 (23.0)

11 (25.0)

1 (10.0)

26 (22.6)

     Others

2 (3.3)

2 (4.5)

0 (0.0)

4 (3.5)

Postoperative hospital stay^b (day)

8.0 (5.0–12.0)

10.0 (7.0–27.0)

19.0 (11.0–29.0)

9.0 (5.0–29.0)

<0.001